Coformulations are a novel pharmaceutical development in diabetology. They are composed of two medicinal products, both of which maintain their distinct pharmacokinetic and pharmacodynamic properties. Currently available coformulations include combinations of basal and rapid-acting insulin, and basal and glucagon-like peptide 1 receptor agonists (GLP1RA). This review describes three coformulations which are in advanced stages of development, or are approved in certain markets. We discuss the basic and clinical pharmacology of these drugs, while describing clinical usage of the commercially available insulin degludec aspart (IDegAsp).
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COFORMULATIONS IN DIABETOLOGY
Fixed dose combination (FDCs) and fixed ratio combinations (FRCs) or fixed proportion combination (FPCs) are an integral and wellaccepted part of diabetes care. Oral FDCs are convenient to use and well tolerated in patients, and their efficacy has been well demonstrated [1] . Injectable FRCs or FPCs, such as pre-mixed insulin, are also widely used in diabetes management [1] . These FRCs provide convenient, effective and safe glycemic control. However, the traditionally available FRCs are mixtures of two components which merge with each other in the solution, and may lose their distinct pharmacokinetic and pharmacodynamic profiles [1] . This may lead to limitations in onset of peak or duration of action, and may result in suboptimal efficacy.
from the same therapeutic class (e.g., a rapid acting insulin combined with a basal insulin) or from different therapeutic classes (e.g., a basal insulin combined with a glucagon-like peptide 1 receptor agonist [GLP1RA]). The dictionary defines ''formulation'' as ''the act, process or result of formulating or reducing to a formula'' or ''a medicinal preparation'', and defines coformulation as ''the act of packaging more than one drug into one pill'' [2] . It must be noted that no injectable coformulations have been described as such until now. The word ''injection'' when used in terms of drug dosage refers to solution, suspension and emulsion, including those produced from powders or concentrated solutions. Various oral coformulations such as multivitamins, vitamin B complex and certain antibiotics (e.g., co-amoxiclav) are available for intravenous use. Such pharmaceutical advances, however, have not been available in the anti-diabetic segment so far. This is because the challenges of producing and combining biologically engineered molecules, such as insulin and GLP1RA, are infinitely greater than those utilizing synthetic chemical compounds.
In this review, we define injectable pharmaceutical coformulations as preparations, and which also maintain their distinct pharmacological properties. These are distinct from the pre-mixed insulins that have been available over the last 50 years ( Table 1) .
CLASSIFICATION
In this review, we discuss the following coformulations, which are based on insulin as a common compound. These coformulations may or may not include a GLP1RA. [3] .
Insulin degludec has a very long duration of action ([42 h) with four times lower glycemic variability than insulin glargine at steady-state concentration [3] ; this translates into a much lower risk of hypoglycemia, especially nocturnal hypoglycemia, as seen in various clinical trials [4] .
Pharmacokinetics and Pharmacodynamics
These two insulin analogs have been coformulated in such a manner that they neither interfere with the pharmacokinetics of each other nor cause any change in the mode of action of each other [5] . Receptor affinities of various newer insulins have always been a cause of concern, especially insulin-like growth factor 1 (IGF-1) receptor binding affinity, which could induce mitogenesis and carcinogenicity when at high levels. These properties of insulin degludec [6] and insulin aspart [7] were respectively investigated in vitro, as briefly mentioned in Table 2 .
Clinical Trial Program
The efficacy and safety of IDegAsp has been studied in the phase 3 BOOST clinical trial program. These clinical studies were conducted in patients with both type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), both as once-daily (OD) and twice-daily (BID)
dosing. The endpoints of this trial are summarized in Table 3 .
Regulatory Approval Status
IDegAsp has recently received market approval in the European Union, Japan, Mexico, India and Bangladesh for the treatment of T1DM and T2DM.
Posology
As per the IDegAsp label, IDegAsp can be administered OD or BID with main meal(s). In IDegAsp is missed, patients should not take an extra dose to make up for a missed dose, but can take the missed dose with the next main meal of that day and then resume the usual dosing schedule the following day.
The recommended total daily starting dose for patients with T2DM is 10 unit with the main meal(s), followed by individual dosage adjustments. The recommended starting dose of IDegAsp in patients with T1DM is 60-70% of 
Special Populations
IDegAsp can be used in elderly patients (aged [65 years) and in renal and hepatic impaired patients with intensified glucose monitoring [8] . The insulin dose should be adjusted on an individual basis. The safety and efficacy of IDegAsp in children and adolescents aged under 18 years have not been established, and so this coformulation is not currently approved for use in children.
INSULIN DEGLUDEC AND LIRAGLUTIDE
Insulin degludec and insulin liraglutide (IDegLira) is a fixed-dose, once-daily combination of ultra-long-acting insulin degludec and liraglutide, a GLP1RA. It has been developed for use in patients with T2DM and can be given in a single, daily subcutaneous injection.
The use of insulin is often associated with hypoglycemia and weight gain, hence delaying the initiation and intensification of the insulin regimen [14] . When used alongside insulin, GLP1RAs can play an important complimentary role, as their use has been associated with a lower incidence of hypoglycemia and weight loss; this could be due to loss of appetite, as is often seen with the use of GLP1RA [14] . Therefore, when administered together, this combination can be very successful in the management of T2DM. The combined use of basal insulin and GLP1RA analogs has also been jointly recommended by the American Diabetes Association (ADA) and
European Association for the Study of Diabetes (EASD) [14] .
Rationale
Many studies combining basal insulin analogs with GLP1RA have shown synergistic beneficial effects of these therapies with better safety profiles.
In a 26-week randomized, open-label study of patients with poorly controlled T2DM, addition of liraglutide to metformin treatment followed by intensification with basal insulin (insulin detemir [IDet]) showed that 61% of participants completing the run-in achieved glycated hemoglobin (HbA1C) levels of \7% (mean change -1.3%) compared with liraglutide alone [15] . At 26 weeks, HbA1C further decreased by 0.5% with IDet versus a 0.02% increase without IDet (estimated treatment difference -0.52; 95% confidence interval [CI] -0.68 to -0.36; p\0.0001). At week 26, HbA1C levels of \7% were achieved in 43% of patients taking IDet versus 17% patients not taking IDet. Sustained weight loss was observed during the study; however, there were higher rates of minor hypoglycemia in patients treated with IDet compared to without IDet (9.2 versus 1.3%, p = 0.004) [15] .
The efficacy and safety of adding long-acting GLP1RA liraglutide OD versus adding shortacting insulin aspart (IAsp) OD to long-acting insulin degludec (IDeg) OD ? metformin in subjects with T2DM was first investigated in the BEGIN: VICTOZA ADD-ON trial [16] .
Eligible subjects completing 104 weeks of treatment with IDeg ? metformin in preceding trials were randomized to intensify treatment by adding either liraglutide or IAsp OD, on top of IDeg ? metformin if their HbA1C was C7% (C53 mmol/mol). After 104 weeks, a third arm was included to evaluate the durability of IDeg to maintain glycemic control over an additional 26 weeks comprising non-randomized subjects with HbA1C of \7.0%. The results showed that IDegLira reduced HbA1C (-0.74% points) significantly more than IDegAsp (-0.39% points; p = 0.0024). 49.4% of subjects in the IDegLira arm and only 7.2% in the IDegAsp arm achieved HbA1C of \7% without confirmed hypoglycemia or severe hypoglycemia, and without weight gain (p\0.0001). IDegLira subjects had significantly less confirmed and nocturnal confirmed hypoglycemia, and significantly greater weight loss (-2.8 kg)
versus IDegAsp (?0.9 kg; p\0.0001) [16] .
Pharmacokinetics and Pharmacodynamics
IDeg is a basal insulin with an ultra-long duration of action that forms soluble multihexamers at the injection site following subcutaneous administration and a half-life of 24 h [17] . Liraglutide is a human GLP1RA with 97% homology. The peptide precursor of liraglutide is produced using recombinant DNA technology in yeast (Saccharomyces cerevisiae). In a dose escalation study in healthy subjects, five consecutive dose levels (1.25, 5.0, 7.5, 10.0 and 12.5 lg/kg) of liraglutide were given subcutaneously on day 1 and days 5 to 11. A steady state was observed after three doses and the half-life was determined to be 12.6 ± 1.1 h [18] .
Phase 3 Clinical Trial Program
The DUal Action of Liraglutide and Insulin Degludec in Type 2 Diabetes (DUAL) trial includes two phase 3a trials encompassing around 2000 people with T2DM. It was designed to study the efficacy and safety of combined use of insulin degludec and liraglutide. All treatments in both the trials were given subcutaneously and could be given at any time of day, provided the chosen time was used consistently every day.
The main features and the study results of both the DUAL programs (I and II) are shown in Table 4 .
Regulatory Approval Status
IDegLira has been given market authorization by the European Medical Agency (EMA), which is valid throughout the EU [21] .
INSULIN GLARGINE AND LIXISENATIDE
Lixisenatide is a new selective once-daily GLP1RA in development for the treatment of T2DM [22] . In a 13-week, phase II study, the optimal dose of lixisenatide was found to be 20 lg OD. At this dose, significant improvements in HbA1C versus placebo were observed, with a good efficacy/tolerability ratio [22] . Lixisenatide has demonstrated dose-dependent improvements in post-meal glucose levels and suppression of postprandial glucagon secretion in patients with T2DM insufficiently controlled with metformin, as well as pharmacodynamic effects consistent with a glucose-dependent effect on insulin secretion and suggested improvements in b-cell function [23] .
Clinical Trial Program
A phase 3 clinical trial program named GetGoal, which included 10 clinical trials, has been carried out to establish the safety and efficacy of insulin glargine and lixisenatide combination for the management of patients of T2DM. There was a trend in weight decreases in patients treated with lixisenatide, with no statistically significant differences between lixisenatide and placebo Symptomatic hypoglycemia was similar in patients not receiving sulfonylureas, but was more frequent with lixisenatide versus placebo (32.6 versus 28.3%)
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